Biocompatibility_study_of_different_hyaluronan_products_for_inta_articular_treatment_of_knee-1.jpg

Treatment of knee osteoarthritis with different hyaluronan products

Biocompatibility study of different hyaluronan products for intra-articular treatment of knee osteoarthritis.

Article specifications

This clinical trial was published in 2019 in Journal of BMC Musculoskelet Disord. (IF2014: 2.63) by Japanese specialists. Biocompatibility of three multiple-injection IA-HA products available in the global market investigated. These included SUPARTZ FX™, a medium range molecular weight HA derived from rooster comb (Avian-HA); ORTHOVISC®, a high range molecular weight HA obtained through biological fermentation (Bio-HA); and SYNVISC®, a high molecular weight cross-linked hyaluronan derived from rooster comb (Avian-CL-HA). Rabbit knee joint tissues were histologically and biochemically examined after IA injection of the products. Furthermore, we compared the amounts of impurities in the IA-HA products.

 

Results

The present results clearly demonstrate that the biocompatibility of Avian-HA is comparable to that of Bio-HA, and they were both considered to have a favorable safety profile for the treatment of symptomatic OA of the knee. However, immunostimulatory activity was observed after injection of Avian-CL-HA: this might be a result of its unique cross-linking structure and/or the considerable amount of (1 → 3)-β-D-glucan impurity present in the formulation.

Tags: Japan BMC Musculoskeletal Disorders Clinical trial 2019

Hayland Center

© 2018 HYLAND.CENTER ALL RIGHTS RESERVED